AVBP
Live chart
What they do
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib.
For information only · Important disclosures
Grades vs sector
No sector grades for AVBP yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-12 | -0.98 | -1.05 | -6.7% |
| 2026-05-11 | -0.89 | -0.96 | -7.4% |
| 2026-03-05 | -0.85 | -0.78 | +7.7% |
| 2025-11-10 | -0.78 | -0.83 | -6.0% |
| 2025-08-11 | -0.71 | -0.90 | -26.5% |
| 2025-05-12 | -0.69 | -1.90 | -175.4% |
| 2025-03-03 | -0.78 | -0.61 | +21.9% |
| 2024-11-14 | -1.07 | -0.61 | +42.8% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | – |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $0 | – |
| 2025-06-30 | $0 | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Stats refreshed 2026-10-21 18:28:48 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026